House approves language to protect 340B Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The House of Representatives has approved bipartisan language “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers’ unlawful actions that have resulted in overcharges to 340B covered entities.” 

The appropriations bill amendment, authored by Reps. Abigail Spanberger (D-Va.) and David McKinley (R-W.V.), pertains to drug companies that have stopped offering required discounts to safety-net hospitals, health centers, and clinics on drugs dispensed at community-based pharmacies.

“My 340B-related amendment sends a message to big pharmaceutical companies: Stop hiking drug prices on consumers and discriminating against our 340B providers and pharmacies,” Spanberger said in a House floor speech.

“The actions of several drug companies to deny 340B discounts for drugs dispensed at community pharmacies are harming safety-net providers and the patients they serve while increasing drugmakers’ profits,” 340B Health President and CEO Maureen Testoni said in a statement.

Table of Contents

YOU MAY BE INTERESTED IN

John A. Ellerton, the principal investigator of the Nevada Cancer Research Foundation NCI Community Oncology Research Program, has won the 2021 Harry Hynes Award. The award is given annually to NCORP PIs for outstanding contribution to clinical trials and community research. In 1983, Ellerton’s group, then called the Southern Nevada Research Foundation, was among the...

From 1992 to 2008, Ellen Stovall was the president and CEO of NCCS, the oldest survivor-led organization advocating for quality cancer care for all Americans. This video, filmed and produced in 2008, features interviews from NCCS co-founders Dr. Patti Ganz and Dr. Fitzhugh Mullan, Dr. Julia Rowland, Dr. Zeke Emanuel, the late General H. Norman Schwarzkopf, and others.

Login